Estrella Immunopharma, Inc. (Nasdaq: ESLA), the California-based clinical-stage biotechnology company developing engineered T-cell therapies for cancer and autoimmune diseases, announced on October 14, 2026, that it has activated Intermountain Health LDS Hospital in Salt Lake City, Utah, as the fifth clinical site for its STARLIGHT-1 Phase 1/2 study. The trial is evaluating EB103, an investigational CD19-directed ARTEMIS T-cell therapy, in adults with relapsed or refractory B-cell non-Hodgkin lymphoma who have limited treatment options.
The additional center joins UC Davis Comprehensive Cancer Center, Baylor Scott & White Research Institute, Oregon Health & Science University and University Hospitals Cleveland Medical Center. Estrella expects the Utah hospital to begin screening and enrolling participants after completing site initiation activities. The expansion is intended to support recruitment into the ongoing Phase 2 portion of STARLIGHT-1, which is evaluating EB103 at the recommended dose selected during earlier testing.
The operational milestone follows preliminary clinical findings from nine patients treated during Phase 1 dose escalation. Among five evaluable patients receiving the higher dose, all five achieved a complete response at the one-month assessment. Estrella subsequently reported that patients who achieved complete responses without central nervous system involvement remained in remission at the six-month assessment, providing encouraging but limited evidence of response durability.
However, STARLIGHT-1 remains a Phase 1/2 study rather than a pivotal Phase 3 trial. Its current expansion is intended to generate additional safety and efficacy information that may guide future registration studies. The encouraging early results require confirmation in more patients, particularly because the trial has no randomized comparator and the initial response population was extremely small.
Why is Estrella expanding STARLIGHT-1 to five clinical centers?
Clinical site expansion can help a cellular therapy developer reach a wider group of eligible patients and reduce dependence on enrollment at one institution. This is particularly important in relapsed or refractory B-cell non-Hodgkin lymphoma, where trial participants may have already received several treatments and face additional eligibility restrictions. Patients may also need access to specialized centers capable of administering engineered T-cell therapies.
Estrella initially conducted STARLIGHT-1 through UC Davis Comprehensive Cancer Center in California. Baylor Scott & White Research Institute in Dallas became the second site in July 2026, followed by Oregon Health & Science University in Portland in early August. University Hospitals Cleveland Medical Center was added later that month, bringing the network to four centers before the October Utah expansion.
The fifth site, Intermountain Health LDS Hospital, adds another center with cellular therapy experience and extends the study’s geographic reach. The company expects the hospital to begin screening and enrollment after completing the required initiation procedures. Site activation does not mean that patients have already received EB103 at the new location.
The trial registry was updated at the beginning of October to reflect a planned enrollment increase from 21 to 27 participants. The estimated primary completion date also moved from December 2026 to July 2027, with overall study completion now anticipated in July 2028. These dates are estimates and may change as recruitment and follow-up progress.
The expanded network may improve recruitment flexibility, but the announcement does not establish that the study will finish ahead of schedule. Cellular therapy enrollment involves patient identification, manufacturing arrangements, clinical eligibility review and treatment coordination. Adding centers can support those activities without guaranteeing faster enrollment.
How does EB103’s ARTEMIS receptor differ from conventional CAR-T therapy?
EB103 is an engineered T-cell therapy designed to recognize CD19, a protein expressed on many malignant B cells. Like conventional CD19-directed CAR-T treatments, it uses modified immune cells intended to identify and destroy cancer cells carrying the target antigen. The difference lies in the receptor architecture and the biological signaling mechanism used to activate the modified cells.
Estrella’s ARTEMIS technology was developed by Eureka Therapeutics, which is also the company’s parent organization. The platform is designed to mimic selected features of the natural T-cell receptor signaling process rather than using the conventional chimeric antigen receptor architecture. According to the developer, the approach may provide more physiological activation and regulation following recognition of tumor cells.
Conventional CAR-T receptors generally combine an antigen-binding component with intracellular activation and costimulatory signaling domains. These constructs have demonstrated substantial efficacy in several blood cancers but can produce important treatment-related toxicities, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. They also have limitations involving relapse, manufacturing complexity and eligibility for treatment.
Estrella believes its receptor design could help address selected safety and durability challenges. However, the underlying mechanism does not establish that EB103 is clinically safer than approved CAR-T products. Such a conclusion would require sufficiently large and appropriately designed comparative studies.
The current Phase 1/2 investigation is intended to determine whether the platform can produce meaningful antitumor responses while maintaining an acceptable safety profile. The results may inform later development but cannot yet validate a claim of superiority over established cellular therapies.
What did the initial nine-patient STARLIGHT-1 trial establish about response?
The completed Phase 1 dose-escalation portion enrolled nine patients with heavily pretreated B-cell non-Hodgkin lymphoma. Participants had received a median of three prior treatment lines, and approximately 89% had undergone at least two earlier treatment regimens. The company classified a substantial proportion of the population as high risk, including patients with aggressive lymphoma characteristics and central nervous system involvement.
Two dose levels were investigated. Three patients received 2.5 million receptor-positive T cells per kilogram, while six received 5 million receptor-positive cells per kilogram. The higher-dose group was selected for further assessment after the initial safety and response observations.
Among the six patients in the higher-dose cohort, five were evaluable for the one-month efficacy assessment. All five achieved complete responses, resulting in a 100% complete response rate within that small evaluable subgroup. The sixth patient died from sepsis on Day 18, which the investigator considered unrelated to EB103, and was not included in the evaluable response denominator.
That denominator is central to interpreting the result. Five responses among five evaluable patients represent an encouraging early signal, but they do not mean that all six treated patients in the higher-dose cohort achieved complete responses. They also do not establish a 100% response rate for the nine-patient Phase 1 population or predict the outcome of subsequent dose expansion.
In February 2026, Estrella reported that complete response durations ranged from approximately three to 18 months and that the median duration of complete response had not been reached at the January 28 data cutoff. This suggests that several responses were ongoing, although the available follow-up was too limited to establish a mature duration-of-response estimate.
The company’s July update subsequently reported continued complete responses at six months among evaluable Phase 1 participants without central nervous system involvement. These findings add follow-up information but do not establish long-term survival benefit or the likelihood of relapse in a larger treated population.
Why does the early safety profile require careful interpretation?
The initial Phase 1 experience included no serious adverse events assessed by investigators as related to EB103. That finding supported review by an independent data safety monitoring board, which recommended advancement into the expansion portion of STARLIGHT-1. However, the absence of treatment-related serious adverse events does not mean that patients experienced no important toxicities.
According to Estrella’s annual regulatory filing, cytokine release syndrome occurred in all nine treated Phase 1 patients. The reported events were grade 1 or 2, with no grade 3 or higher cytokine release syndrome observed in the evaluated population. These findings suggest manageable early inflammatory toxicity under the clinical conditions used.
The company also reported transient low-grade immune effector cell-associated neurotoxicity syndrome in a majority of participants. Symptoms were managed through standard clinical care, with a reported median duration of approximately two days. The observations are relevant because neurotoxicity remains an important concern across engineered T-cell treatment programmes.
A patient in the higher-dose cohort died from grade 5 sepsis. Although the investigator assessed the event as unrelated to EB103, the occurrence remains important when evaluating overall treatment experience in a heavily pretreated population. Infection risk may be influenced by prior therapies, disease-related immune dysfunction and the treatment procedures surrounding cellular therapy.
The Phase 2 expansion will provide a larger safety dataset and additional information about the reproducibility of the initial findings. Rare complications or effects occurring after longer follow-up cannot be reliably excluded from nine patients. Any future comparative safety claim will require stronger evidence.
Which lymphoma patients could benefit from a new CD19-directed cellular therapy?
B-cell non-Hodgkin lymphoma includes several malignancies arising from different stages of B-cell development. These diseases vary in aggressiveness, molecular characteristics and response to treatment. Some patients achieve prolonged remission with conventional immunochemotherapy, while others experience persistent disease or relapse after multiple treatment lines.
CD19-directed cellular therapies have transformed treatment for selected patients with relapsed or refractory B-cell malignancies. Approved products include therapies developed by Gilead Sciences’ Kite subsidiary, Bristol Myers Squibb and Novartis. These medicines have demonstrated meaningful response rates in defined populations, although toxicity, relapse and access remain important limitations.
Estrella is investigating EB103 in a population that includes patients with particularly difficult clinical circumstances. The STARLIGHT-1 protocol permits selected patients with high-grade B-cell lymphoma, primary or secondary central nervous system lymphoma and other high-risk characteristics. This could provide an opportunity to study a population not always represented in earlier commercial CAR-T development programmes.
However, eligibility for an investigational study does not establish that EB103 is appropriate for every patient who cannot receive an approved product. The trial’s criteria, treatment requirements and clinical risk assessment remain important. Its broad study population may also create challenges when interpreting outcomes across biologically different lymphoma types.
A larger clinical dataset will need to determine whether the encouraging early responses are reproducible across these subgroups. Disease-specific results may become particularly important if Estrella eventually pursues a registration programme focused on a narrower indication.
How does Estrella’s Phase 2 expansion differ from a registrational Phase 3 study?
STARLIGHT-1 is registered as NCT06343311, a multicenter, open-label Phase 1/2 study. The completed initial stage used dose escalation to characterize safety and determine a recommended Phase 2 dose. The ongoing expansion stage is intended to investigate additional patients at that selected dose and gather more information about preliminary efficacy and tolerability.
The study does not randomly assign participants between EB103 and an established treatment comparator. Investigators and participants know that EB103 is being administered, meaning the evidence must be interpreted within the limitations of an uncontrolled design. Tumor response criteria provide useful objective measures, but they cannot remove every source of uncertainty associated with patient selection and treatment history.
The current registry lists an estimated enrollment of 27 patients. This planned total is appropriate for an early-stage investigation but remains small compared with many later-stage oncology studies. The resulting information may help determine whether there is sufficient evidence to justify further investment and registration planning.
Estrella has stated that the expansion cohort will inform its future pivotal trial strategy. That does not mean the existing study is already a pivotal investigation or that the FDA has agreed to approve EB103 based on the preliminary findings. Additional regulatory discussions and clinical evidence will be required.
The company’s October announcement is therefore an operational development milestone. It does not report a new complete response rate, a completed Phase 2 analysis or successful achievement of a registrational endpoint.
What does Estrella’s June 2026 financial position mean for trial expansion?
Clinical site activation comes alongside a material financial challenge. Estrella’s quarterly filing for the period ended June 30, 2026, reported cash and cash equivalents of approximately $146,700, compared with current liabilities of roughly $9.3 million. The company had an accumulated deficit of approximately $41.6 million and used around $8.5 million in cash for operating activities during the first six months of the year.
Management concluded in the filing that substantial doubt existed about the company’s ability to continue as a going concern. This assessment reflected recurring operating losses, limited cash resources and expected working capital requirements. It is a financial reporting conclusion rather than confirmation that the company has ceased operations.
Estrella has used equity financing arrangements to support its activities, including a registered direct offering completed in January 2026. However, potential future financing capacity should not be treated as cash already available. The October clinical site announcement did not disclose a new financing transaction sufficient to eliminate the concerns identified in the June financial statements.
The company also has significant obligations associated with its development relationship with Eureka Therapeutics. Its regulatory filing described approximately $8.3 million in accrued milestone obligations to the related party as of June 30. The broader EB103 clinical services arrangements could involve additional expenditures as enrollment and treatment progress.
For investors, this creates an important distinction between scientific development and financial execution. Expanding the number of clinical centers may support a stronger dataset, but continued patient treatment and follow-up require adequate funding. Future capital transactions could also introduce dilution, depending on their structure.
Estrella’s development prospects therefore depend on both the quality of emerging EB103 results and its ability to maintain the financial resources necessary to complete the programme.
Why does Estrella’s EB104 pipeline matter beyond the current lymphoma study?
Estrella is also developing EB104, an investigational ARTEMIS-based T-cell therapy intended to recognize both CD19 and CD22. The programme is designed to explore whether dual-antigen targeting could address some forms of resistance associated with treatment directed toward a single surface protein. It remains separate from EB103 and has not been established as an effective clinical treatment.
Target loss or reduced antigen expression can contribute to relapse after certain cellular therapies. A dual-target approach could theoretically provide additional opportunities to recognize malignant B cells that do not express sufficient levels of one antigen. However, targeting two proteins does not automatically prevent resistance or establish stronger antitumor activity.
The EB104 programme could eventually broaden Estrella’s cellular therapy pipeline beyond the CD19-directed strategy being tested in STARLIGHT-1. That potential diversification may be relevant commercially, but it also requires additional development resources. The company’s immediate clinical priority remains generating convincing EB103 results.
Success in EB103 could provide practical experience with the ARTEMIS platform, manufacturing and clinical administration. Nevertheless, each engineered T-cell product requires its own evidence of safety, biological activity and treatment benefit. The current Phase 1 response findings cannot be transferred directly to EB104.
What must the five-site STARLIGHT-1 programme establish before pivotal development?
The expanded study needs to show that EB103 can reproduce its early complete response findings across additional patients and treatment centers. Confirmed response rates, duration of response and progression-related outcomes will help investigators assess the treatment’s clinical potential. The size and composition of the evaluable population will remain important for interpreting any headline efficacy percentage.
Investigators will also need to characterize cytokine release syndrome, neurotoxicity, infections and other adverse events as more participants receive the selected dose. Long-term monitoring will be necessary because engineered T-cell therapies can produce delayed complications and may remain detectable after administration. The study protocol includes extended follow-up beyond the active assessment period.
A multicenter expansion may provide additional information about the consistency of manufacturing and treatment administration. Autologous cell therapies involve collecting cells from individual patients, modifying them and returning the finished product for treatment. These activities create logistical requirements that can influence clinical and commercial feasibility.
Estrella must also determine whether the strongest opportunity lies in a particular lymphoma subgroup or a broader relapsed and refractory population. The preliminary complete response findings span a small and clinically heterogeneous group, making disease-specific conclusions premature. Selecting an appropriate future comparator and trial population will be critical to any registrational strategy.
The activation of Intermountain Health LDS Hospital expands STARLIGHT-1’s reach to five United States centers and supports enrollment into a more informative Phase 2 dataset. The original five complete responses among five evaluable higher-dose patients provide an encouraging basis for continued investigation, but the results are not sufficient to establish long-term efficacy or superiority over approved cellular therapies.
The next decisive milestones are additional enrollment, updated response durability and a larger safety analysis, accompanied by sufficient financing to complete the programme. If EB103 can reproduce its early findings across more patients while maintaining acceptable tolerability, Estrella may have a stronger foundation for pivotal development. Until then, the October 2026 site expansion represents progress in clinical execution rather than confirmation of a new lymphoma treatment.
